Vulvovaginal candidiasis (WC), the second most common form of vaginiti
s, particularly affects women of childbearing age. Since the 1970s, se
veral new agents have become available for the treatment of VVC. This
review focuses on options for the treatment of this condition, critica
lly evaluating the relevant published studies. For the treatment of ac
ute episodes of VVC in nonpregnant women, several topical and oral ant
ifungal agents are clinically and mycologically effective, Topical age
nts should be considered the first line of therapy; however, oral agen
ts are sometimes associated with better compliance among patients, For
acute episodes in pregnant women, a topical agent is the treatment of
choice. Until data become available on the treatment of VVC in women
infected with human immunodeficiency virus (HIV), the same approach as
that used for women without HIV infection should be considered as pre
viously written. For recurrent VVC, the optimal maintenance therapy ha
s not yet been established; however, administration of low-dose oral k
etoconazole (100 mg/d) has proven effective. Well-designed studies of
the best therapy for VVC in women with HIV infection and for recurrent
VVC are urgently needed.